Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accounts Payables (2016 - 2026)

Ironwood Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $2.9 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 36.25% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 36.25% increase, with the full-year FY2025 number at $2.9 million, up 36.25% from a year prior.
  • Accounts Payables hit $2.9 million in Q4 2025 for Ironwood Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for IRWD hit a ceiling of $7.8 million in Q4 2023 and a floor of $118000.0 in Q1 2023.
  • Historically, Accounts Payables has averaged $2.4 million across 5 years, with a median of $1.5 million in 2025.
  • Biggest five-year swings in Accounts Payables: crashed 79.01% in 2021 and later skyrocketed 5172.88% in 2024.
  • Tracing IRWD's Accounts Payables over 5 years: stood at $935000.0 in 2021, then plummeted by 48.34% to $483000.0 in 2022, then skyrocketed by 1521.12% to $7.8 million in 2023, then tumbled by 72.84% to $2.1 million in 2024, then soared by 36.25% to $2.9 million in 2025.
  • Business Quant data shows Accounts Payables for IRWD at $2.9 million in Q4 2025, $1.6 million in Q3 2025, and $1.4 million in Q2 2025.